Drug | Cell Type | Cr,AB | Cr,BA | Papp,AB | Papp,BA | ER |
---|---|---|---|---|---|---|
μM | 10−6 cm/s | |||||
Atorvastatin | MDCK | 0.0086 | 0.019 | 0.42 | 0.31 | 0.73 |
Atorvastatin | MDR1 | 0.0041 | 0.47 | 0.2 | 7.7 | 38 |
Atorvastatin | MDCK + CsA | 0.007 | 0.0044 | 0.35 | 0.072 | 0.21 |
Atorvastatin | MDR1 + CsA | 0.015 | 0.017 | 0.73 | 0.27 | 0.37 |
Digoxin | MDCK | 0.0058 | 0.12 | 0.29 | 2 | 7.1 |
Digoxin | MDR1 | 0.0014 | 0.3 | 0.074 | 5 | 73 |
Digoxin | MDCK + CsA | 0.0047 | 0.011 | 0.23 | 0.18 | 0.79 |
Digoxin | MDR1 + CsA | 0.0044 | 0.017 | 0.21 | 0.27 | 1.3 |
Labetalol | MDCK | 0.017 | 0.078 | 0.82 | 1.3 | 1.6 |
Labetalol | MDR1 | 0.018 | 1.6 | 0.87 | 27 | 31 |
Labetalol | MDCK + CsA | 0.013 | 0.046 | 0.63 | 0.75 | 1.2 |
Labetalol | MDR1 + CsA | 0.07 | 0.17 | 3.4 | 2.7 | 0.8 |
Loperamide | MDCK | 0.018 | 0.28 | 0.89 | 4.5 | 5.1 |
Loperamide | MDR1 | 0.0059 | 4 | 0.29 | 65 | 220 |
Loperamide | MDCK + CsA | 0.03 | 0.14 | 1.5 | 2.2 | 1.5 |
Loperamide | MDR1 + CsA | 0.32 | 1.1 | 16 | 17 | 1.1 |
Minoxidil | MDCK | 0.0085 | 0.034 | 0.42 | 0.56 | 1.3 |
Minoxidil | MDR1 | 0.018 | 0.16 | 0.91 | 2.7 | 3.1 |
Minoxidil | MDCK + CsA | 0.012 | 0.025 | 0.61 | 0.4 | 0.67 |
Minoxidil | MDR1 + CsA | 0.017 | 0.052 | 0.84 | 0.87 | 1 |
Pitavastatin | MDCK | 0.025 | 0.044 | 1.2 | 0.71 | 0.57 |
Pitavastatin | MDR1 | 0.018 | 1.1 | 1.1 | 21 | 20 |
Pitavastatin | MDCK + CsA | 0.027 | 0.025 | 1.3 | 0.41 | 0.31 |
Pitavastatin | MDR1 + CsA | 0.088 | 0.083 | 5.1 | 1.5 | 0.31 |
Cr,AB, concentration in receiver (basolateral side) upon apical dosing; Cr,BA, concentration in receiver (apical side) upon basolateral dosing; Papp,BA, apparent permeability calculated from B-A experiments; Papp,AB, apparent permeability calculated from A-B experiments; ER, efflux ratio.